Document is current
Any future updates will be listed below
-
Authors
Mahic, Milada
Bozorg, Ali
DeCourcy, Jonathan
Golden, Keisha
Gibson, Gregor
Taylor, Christian
Scowcroft, Anna http://orcid.org/0000-0002-4727-9243
-
Funding
Funding for this research was provided by:
UCB Pharma
- License Information
-
More Information
Article History
Received: 23 September 2022
Accepted: 14 May 2023
First Online: 29 June 2023
Declarations
:
: This research obtained ethics approval from the Western Institutional Review Board, sponsor protocol number: AG8768. The Adelphi Disease Specific Programme™ is Health Insurance Portability and Accountability Act compliant, and all data were aggregated and de-identified. Using a check box, patients and physicians provided informed consent to take part in the Adelphi Myasthenia Gravis Disease Specific Programme™ market research survey, on which this secondary data analysis is based. Data were collected in such a way that patients and physicians could not be identified directly.
: Not applicable.
: Milada Mahic is a former employee of UCB Pharma and is now employed by Vertex Pharmaceuticals. Ali Bozorg is a former employee of UCB Pharma and is now employed by Otsuka Pharmaceutical Development and Commercialization, Inc. Anna Scowcroft is an employee and stockholder of UCB Pharma. Keisha Golden, Gregor Gibson and Jonathan DeCourcy are employees of Adelphi Real World. Christian Taylor is a former employee of Adelphi Real World and does not currently have an affiliation to any organization.
